1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next

 
• By Jessica Merrill

The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.

Building Blocks
Biohaven is building out a long-term growth strategy • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd.'s first commercial product, Nurtec ODT (rimegepant), is off to a solid start as the first and only CGRP inhibitor with US Food and Drug Administration approval for both acute treatment and prevention of migraine. As Biohaven focuses on expanding the drug’s use in both settings, it is also building out a pipeline of drugs to address additional neurological conditions, as investor focus turns to what comes next.

Nurtec ODT generated $92.9m in second quarter sales, Biohaven reported on 9 August. The drug is the company’s first commercial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.